The appointment of Ken James (formerly SVP, GSK Healthcare R&D) to the Board of Futura Medical represents a timely step by the company, supporting the commercialisation of its strong portfolio of OTC and prescription products. We continue to expect exciting newsflow ahead: first regulatory approval of CSD500 following a successful shelf life extension project and headline data from the clinical trial of MED2002 are both expected in Q2 2016, and a near-term commercial deal for a topical pain reli ....
07 Mar 2016
Non-executive director appointment shows commercialisation intent N+1 Singer view
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Non-executive director appointment shows commercialisation intent N+1 Singer view
Futura Medical plc (FUM:LON) | 35.8 0 (-0.1%) | Mkt Cap: 108.0m
- Published:
07 Mar 2016 -
Author:
Dr Jens Lindqvist -
Pages:
3
The appointment of Ken James (formerly SVP, GSK Healthcare R&D) to the Board of Futura Medical represents a timely step by the company, supporting the commercialisation of its strong portfolio of OTC and prescription products. We continue to expect exciting newsflow ahead: first regulatory approval of CSD500 following a successful shelf life extension project and headline data from the clinical trial of MED2002 are both expected in Q2 2016, and a near-term commercial deal for a topical pain reli ....